Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.84

+0.2%

Dec 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: zeta1961 who wrote (14187)	11/17/2004 5:59:40 PM
From: Biomaven	Read Replies (2) of 52153

A couple of comments on DSCO: First, they showed significantly reduced mortality vs. both Exosurf and Survanta at Day 14 in their RDS trial. P<.0001 vs Exosurf, P not disclosed vs Survanta, but I'm sure it was lower given that there were fewer Survanta patients (it was a 2:2:1 randomization). Deaths were 25/427 (4.7%) vs. 49/509 (9.6%) vs. 27/258 (10.5%) for Surfaxin, Exosurf and Survanta respectively. Note the trial was halted early because of the good results. They show a Kaplan-Meier curve where the divergence becomes even more striking as you go further out to about 20 days. At 2 months, Surfaxin has a 81% survival, with (somewhat surprisingly) Exosurf next with about a 77% survival and Survanta last with about a 74% rate (all eyeballed from graph). The curves stay flat from there. Finally, the ARDS trial in the NEJM was with a surfactant that is different in composition from DSCO's and with a dosage that DSCO clearly believes was inadequate. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next